Haleon plc has committed £65 million to build a new, state‑of‑the‑art oral‑health manufacturing plant in Shanghai’s Lingang New Area, a move that will expand the company’s production footprint in China’s tier‑2 and tier‑3 cities.
The facility will support Haleon’s core oral‑care brands, Sensodyne and Parodontax, and is part of a broader strategy to capture rising demand for trusted, branded oral‑health products in lower‑income markets. The investment follows a £700 million purchase of full ownership of the company’s joint venture with Tianjin TSKF Pharmaceutical in June 2025, underscoring Haleon’s long‑term commitment to the Chinese market.
China is Haleon’s second‑largest market and the world’s largest gum‑health market, valued at roughly £860 million. In 2025 the oral‑health segment grew 7.9 % organically, the strongest performance among all segments, while the company’s overall revenue fell 1.8 % year‑over‑year to £11.03 billion. Haleon’s FY 2025 organic revenue growth of 3 % missed the 4‑6 % medium‑term target, prompting a 3.16 % decline in pre‑market trading. The new facility is intended to strengthen supply capacity, accelerate innovation, and support Parodontax distribution to 30 Chinese cities by the end of 2027.
Brian McNamara, Haleon’s chief executive, said, “China is a strategic priority for Haleon. Building on our established R&D capabilities and strong local team, this investment reflects our long‑term commitment to bringing the very best of our global science and innovation to improve the health and wellbeing of Chinese consumers.” Jayant Singh, global head of oral health, added, “It’s these minor nuances that you need to put into your mix to really drive acceptance.”
The new plant will bring production in‑house, enabling quicker responses to consumer preferences and reducing reliance on external suppliers. Haleon projects £800 million in gross productivity savings over the next five years through a more agile supply chain, and the facility is expected to create a number of jobs in the region. The investment signals Haleon’s confidence in China’s growing middle class and its strategy to sustain long‑term growth in a highly competitive market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.